Resmetirom is an oral, liver-directed, selective THR-β agonist.It reduces hepatic steatosis, inflammation, and fibrosis by selectively activating thyroid hormone receptor-β in hepatocytes,improving lipid metabolism and reducing liver fat.
Approved Indications
Non-cirrhotic non-alcoholic steatohepatitis (NASH) with liver fibrosis
Used to improve metabolic and liver histologic endpoints
Key Features
First-in-class oral selective THR‑β agonist
Liver-targeted, minimal systemic effects
Reduces liver fat, inflammation, and fibrosis
Once-daily oral dosing
Favorable safety profile
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
China [CN] 
Click enlarge Image